Philadelphia chromosome-positive acute lymphoblastic leukemia: Impact of imatinib treatment on remission induciton and allogeneic stem cell tranplantation

被引：3

作者：

Kovacsovics T. ^{[1
]}

Maziarz R.T. ^{[1
]}

机构：

[1] Center for Hematologic Malignancies, Oregon Health Science University, Portland, OR 97239-3098

来源：

Current Oncology Reports | 2006年 / 8卷 / 5期

关键词：

Imatinib; Chronic Myeloid Leukemia; Dasatinib; Imatinib Mesylate; Allogeneic Stem Cell Transplantation;

D O I：

10.1007/s11912-006-0056-y

中图分类号：

学科分类号：

摘要：

Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with the worst patient survival rates of the various acute leukemias. Imatinib mesylate is a novel therapeutic agent that targets the BCR-ABL tyrosine kinase, the molecular abnormality associated with Ph+ ALL. The combination of imatinib with chemotherapy has led to improved and durable treatment responses in adult patients with Ph+ ALL, including the elderly population. Hematopoietic stem cell transplantation has also integrated imatinib into its transplant strategies, with early data suggesting improved progression-free survival without clearly identifiable augmented toxicity. Second-generation tyrosine kinase inhibitors offer potentially even greater improvements on these excellent imatinib-associated outcomes. This review addresses the evolution of the management of Ph+ ALL and is intended to assist in the description of its new natural history. Copyright © 2006 by Current Science Inc.

引用

页码：343 / 351

页数：8

共 61 条

[11] Radich J., Gehly G., Lee A., Et al., Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation, Blood, 89, pp. 2602-2609, (1997)
[12] Lee S., Kim D.W., Cho B., Et al., Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: The potential of real-time quantitative reverse-transcription polymerase chain reaction, Br J Haematol, 120, pp. 145-153, (2003)
[13] Hallbook H., Hagglund H., Stockelberg D., Et al., Autologous and allogeneic stem cell transplantation in adult ALL: The Swedish Adult ALL Group experience, Bone Marrow Transplant, 35, pp. 1141-1148, (2005)
[14] Kassim A.A., Chinratanalab W., Ferrara J.L., Mineishi S., Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'What is the best recipe?, Bone Marrow Transplant, 36, pp. 565-574, (2005)
[15] Cimino G., Pane F., Elia L., Et al., The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: A seven-year update of the GIMEMA 0496 trial, Haematologica, 91, pp. 377-380, (2006)
[16] Mauro M.J., O'Dwyer M.E., Druker B.J., ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: Validating the promise of molecularly targeted therapy, Cancer Chemother Pharmacol, 48, SUPPL. 1, (2001)
[17] Deininger M., Buchdunger E., Druker B.J., The development of imatinib as a therapeutic agent for chronic myeloid leukemia, Blood, 105, pp. 2640-2653, (2005)
[18] Druker B.J., Sawyers C.L., Kantarjian H., Et al., Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome, N Engl J Med, 344, pp. 1038-1042, (2001)
[19] Ottmann O.G., Druker B.J., Sawyers C.L., Et al., A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias, Blood, 100, pp. 1965-1971, (2002)
[20] Wassmann B., Pfeifer H., Scheuring U.J., Et al., Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib, Blood, 103, pp. 1495-1498, (2004)

← 1 2 3 4 5 6 7 →